The use of a lactic acid gel in the treatment and prevention of bacterial vaginosis and urinary tract infections as a challenge to antibacterial therapy. A literature review

Abstract

Bacterial vaginosis and urinary tract infections are common conditions that lead to a decrease in the quality of life and significant economic costs. The review provides up-to-date information on the role of lactic acid in the microbiota of the vagina and urinary tract, as well as on the use of a lactic acid gel in these conditions. Bacterial vaginosis is associated with an increased risk of urinary tract infections. Antibacterial therapy demonstrates statistically significant results in treating exacerbation, but not preventing further relapses, which is due to the possible high ability of bacteria to form biofilms. Lactic acid, unlike hydrogen peroxide, is involved in maintaining the vaginal microbiota and enhancing its protective function against sexually transmitted infections, and indirectly affects the urinary microbiota. This may allow the use of lactic acid for the treatment and prevention of relapses in both bacterial vaginosis and urinary tract infections.

Keywords

bacterial vaginosis / urinary tract infections / lactic acid

References

[1] Diop K, Dufour J-C, Levasseur A, et al. Exhaustive repertoire of human vaginal microbiota. Hum Microbiome J. 2019;11. DOI: 10.1016/j.humic.2018.11.002

[2] Diop K., Dufour J.-C., Levasseur A., et al. Exhaustive repertoire of human vaginal microbiota // Hum. Microbiome J. 2019. Vol. 11. DOI: 10.1016/j.humic.2018.11.002

[3] Ravel J, Gajer P, Abdo Z, et al. Vaginal microbiome of reproductive-age women. Proc Natl Acad Sci USA. 2011;108(Suppl. 1):4680–4687. DOI: 10.1073/pnas.1002611107

[4] Ravel J., Gajer P., Abdo Z., et al. Vaginal microbiome of reproductive-age women // Proc. Natl. Acad. Sci. USA. 2011. Vol. 108, Suppl. 1. P. 4680–4687. DOI: 10.1073/pnas.1002611107

[5] De Seta F, Campisciano G, Zanotta N, et al. The vaginal community state types microbiome-immune network as key factor for bacterial vaginosis and aerobic vaginitis. Front Microbiol. 2019;10. DOI: 10.3389/fmicb.2019.02451

[6] De Seta F., Campisciano G., Zanotta N., et al. The vaginal community state types microbiome-immune network as key factor for bacterial vaginosis and aerobic vaginitis // Front. Microbiol. 2019. Vol. 10. DOI: 10.3389/fmicb.2019.02451

[7] Amabebe E, Anumba DOC. The vaginal microenvironment: the physiologic role of Lactobacilli. Front Med (Lausanne). 2018;5:181. DOI: 10.3389/fmed.2018.00181

[8] Amabebe E., Anumba D.O.C. The vaginal microenvironment: the physiologic role of Lactobacilli // Front. Med. 2018. Vol. 5. P. 181. DOI: 10.3389/fmed.2018.00181

[9] Peebles K, Velloza J, Balkus JE, et al. High global burden and costs of bacterial vaginosis: a systematic review and meta-analysis. Sex Transm Dis. 2019;46(5):304–311. DOI: 10.1097/OLQ.0000000000000972

[10] Peebles K., Velloza J., Balkus J.E., et al. High global burden and costs of bacterial vaginosis: a systematic review and meta-analysis // Sex. Transm. Dis. 2019. Vol. 46. No. 5. P. 304–311. DOI: 10.1097/OLQ.0000000000000972

[11] Bradshaw CS, Morton AN, Hocking J, et al. High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence. J Infect Dis. 2006;193(11):1478–1486. DOI: 10.1086/503780

[12] Bradshaw C.S., Morton A.N., Hocking J., et al. High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence // J. Infect. Dis. 2006. Vol. 193. No. 11. P. 1478–1486. DOI:10.1086/503780

[13] Swidsinski A, Mendling W, Loening-Baucke V, et al. Adherent biofilms in bacterial vaginosis. Obstet Gynecol. 2005;106(5 Pt 1):1013–1023. DOI: 10.1097/01.AOG.0000183594.45524.d2

[14] Swidsinski A., Mendling W., Loening-Baucke V., et al. Adherent biofilms in bacterial vaginosis // Obstet. Gynecol. 2005. Vol. 106. No. 1. Pt. 5. P. 1013–1023. DOI: 10.1097/01.AOG.0000183594.45524.d2

[15] Swidsinski A, Mendling W, Loening-Baucke V, et al. An adherent Gardnerella vaginalis biofilm persists on the vaginal epithelium after standard therapy with oral metronidazole. Am J Obstet Gynecol. 2008;198(1):97.e1–97.e976. DOI: 10.1016/j.ajog.2007.06.039

[16] Swidsinski A., Mendling W., Loening-Baucke V., et al. An adherent Gardnerella vaginalis biofilm persists on the vaginal epithelium after standard therapy with oral metronidazole // Am. J. Obstet. Gynecol. 2008. Vol. 198. No. 1. P. 97.e1–97.e976. DOI: 10.1016/j.ajog.2007.06.039

[17] Hall-Stoodley L, Costerton JW, Stoodley P. Bacterial biofilms: from the natural environment to infectious diseases. Nat Rev Microbiol. 2004;2(2):95–108. DOI: 10.1038/nrmicro821

[18] Hall-Stoodley L., Costerton J.W., Stoodley P. Bacterial biofilms: from the natural environment to infectious diseases // Nat. Rev. Microbiol. 2004. Vol. 2. No. 2. P. 95–108. DOI: 10.1038/nrmicro821

[19] Tenke P, Köves B, Nagy K, et al. Update on biofilm infections in the urinary tract. World J Urol. 2012;30(1):51–57. DOI: 10.1007/s00345-011-0689-9

[20] Tenke P., Köves B., Nagy K., et al. Update on biofilm infections in the urinary tract // World J. Urol. 2012. Vol. 30. No. 1. P. 51–57. DOI: 10.1007/s00345-011-0689-9

[21] Patterson JL, Girerd PH, Karjane NW, et al. Effect of biofilm phenotype on resistance of Gardnerella vaginalis to hydrogen peroxide and lactic acid. Am J Obstet Gynecol. 2007;197(2):170.e1–170.e1707. DOI: 10.1016/j.ajog.2007.02.027

[22] Patterson J.L., Girerd P.H., Karjane N.W., et al. Effect of biofilm phenotype on resistance of Gardnerella vaginalis to hydrogen peroxide and lactic acid // Am. J. Obstet. Gynecol. 2007. Vol. 197. No. 2. P. 170.e1–170.e1707. DOI: 10.1016/j.ajog.2007.02.027

[23] Cherpes TL, Hillier SL, Meyn LA, et al. A delicate balance: risk factors for acquisition of bacterial vaginosis include sexual activity, absence of hydrogen peroxide-producing lactobacilli, black race, and positive herpes simplex virus type 2 serology. Sex Transm Dis. 2008;35(1):78–83. DOI: 10.1097/OLQ.0b013e318156a5d0

[24] Cherpes T.L., Hillier S.L., Meyn L.A., et al. A delicate balance: risk factors for acquisition of bacterial vaginosis include sexual activity, absence of hydrogen peroxide-producing lactobacilli, black race, and positive herpes simplex virus type 2 serology // Sex. Transm. Dis. 2008. Vol. 35. No. 1. P. 78–83. DOI: 10.1097/OLQ.0b013e318156a5d0

[25] Fethers KA, Fairley CK, Hocking JS, et al. Sexual risk factors and bacterial vaginosis: a systematic review and meta-analysis. Clin Infect Dis. 2008;47(11):1426–1435. DOI: 10.1086/592974

[26] Fethers K.A., Fairley C.K., Hocking J.S., et al. Sexual risk factors and bacterial vaginosis: a systematic review and meta-analysis // Clin. Infect. Dis. 2008. Vol. 47. No. 11. P. 1426–1435. DOI: 10.1086/592974

[27] Bhakta V, Aslam S, Aljaghwani A. Bacterial vaginosis in pregnancy: prevalence and outcomes in a tertiary care hospital. Afr J Reprod Health. 2021;25(1):49–55. DOI: 10.29063/ajrh2021/v25i1.6

[28] Bhakta V., Aslam S., Aljaghwani A. Bacterial vaginosis in pregnancy: prevalence and outcomes in a tertiary care hospital // Afr. J. Reprod. Health. 2021. Vol. 25. No. 1. P. 49–55. DOI:10.29063/ajrh2021/v25i1.6

[29] Morris MC, Rogers PA, Kinghorn GR. Is bacterial vaginosis a sexually transmitted infection? Sex Transm Infect. 2001;77(1):63–68. DOI: 10.1136/sti.77.1.63

[30] Morris M.C., Rogers P.A., Kinghorn G.R. Is bacterial vaginosis a sexually transmitted infection? // Sex. Transm. Infect. 2001. Vol. 7. No. 1. P. 63–68. DOI:10.1136/sti.77.1.63

[31] Gong Z, Luna Y, Yu P, et al. Lactobacilli inactivate Chlamydia trachomatis through lactic acid but not H2O2. PLoS One. 2014;9(9). DOI: 10.1371/journal.pone.0107758

[32] Gong Z., Luna Y., Yu P., et al. Lactobacilli inactivate Chlamydia trachomatis through lactic acid but not H2O2 // PLoS One. 2014. Vol. 9. No. 9. DOI:10.1371/journal.pone.0107758

[33] Graver MA, Wade JJ. The role of acidification in the inhibition of Neisseria gonorrhoeae by vaginal lactobacilli during anaerobic growth. Ann Clin Microbiol Antimicrob. 2011;10:8. DOI:10.1186/1476-0711-10-8

[34] Graver M.A., Wade J.J. The role of acidification in the inhibition of Neisseria gonorrhoeae by vaginal lactobacilli during anaerobic growth // Ann. Clin. Microbiol. Antimicrob. 2011. Vol. 10. P. 8. DOI:10.1186/1476-0711-10-8

[35] Conti C, Malacrino C, Mastromarino P. Inhibition of herpes simplex virus type 2 by vaginal lactobacilli. J Physiol Pharmacol. 2009;60(Suppl 6):19–26.

[36] Conti C., Malacrino C., Mastromarino P. Inhibition of herpes simplex virus type 2 by vaginal lactobacilli // J. Physiol. Pharmacol. 2009. Vol. 60. No. 6 Supp. l. P. 19–26.

[37] Aldunate M, Tyssen D, Johnson A, et al. Vaginal concentrations of lactic acid potently inactivate HIV. J Antimicrob Chemother. 2013;68(9):2015–2025. DOI: 10.1093/jac/dkt156

[38] Aldunate M., Tyssen D., Johnson A., et al. Vaginal concentrations of lactic acid potently inactivate HIV // J. Antimicrob. Chemother. 2013. Vol. 68. No. 9. P. 2015–2025. DOI: 10.1093/jac/dkt156

[39] Valore EV, Park CH, Igreti SL, et al. Antimicrobial components of vaginal fluid. Am J Obstet Gynecol. 2002;187(3):561–568. DOI: 10.1067/mob.[phone]

[40] Valore E.V., Park C.H., Igreti S.L., Ganz T. Antimicrobial components of vaginal fluid // Am. J. Obstet. Gynecol. 2002. Vol. 187. No. 3. P. 561–568. DOI: 10.1067/mob.[phone]

[41] Boskey ER, Cone RA, Whaley KJ, et al. Origins of vaginal acidity: high D/L lactate ratio is consistent with bacteria being the primary source. Human Reproduction. 2001;16(9):1809–1813. DOI: 10.1093/humrep/16.9.1809

[42] Boskey E.R., Cone R.A., Whaley K.J., et al. Origins of vaginal acidity: high D/L lactate ratio is consistent with bacteria being the primary source // Human Reproduction. 2001. Vol. 16. No. 9. P. 1809–1813. DOI: 10.1093/humrep/16.9.1809

[43] Witkin SS, Mendes-Soares H, Linhares IM, et al. Influence of vaginal bacteria and D- and L-lactic acid isomers on vaginal extracellular matrix metalloproteinase inducer: implications for protection against upper genital tract infections. mBio. 2013;4(4):e00460–13. DOI:10.1128/mBio.00460-13

[44] Witkin S.S., Mendes-Soares H., Linhares I.M., et al. Influence of vaginal bacteria and D- and L-lactic acid isomers on vaginal extracellular matrix metalloproteinase inducer: implications for protection against upper genital tract infections // mBio. 2013. Vol. 4. No. 4. P. e00460-13. DOI: 10.1128/mBio.00460-13

[45] Hearps AC, Tyssen D, Srbinovski D, et al. Vaginal lactic acid elicits an anti-inflammatory response from human cervicovaginal epithelial cells and inhibits production of pro-inflammatory mediators associated with HIV acquisition. Mucosal Immunol. 2017;10(6):1480–1490. DOI: 10.1038/mi.2017.27

[46] Hearps A.C., Tyssen D., Srbinovski D., et al. Vaginal lactic acid elicits an anti-inflammatory response from human cervicovaginal epithelial cells and inhibits production of pro-inflammatory mediators associated with HIV acquisition // Mucosal. Immunol. 2017. Vol. 10. No. 6. P. 1480–1490. DOI: 10.1038/mi.2017.27

[47] Andersch B, Forssman L, Lincoln K, et al. Treatment of bacterial vaginosis with an acid cream: a comparison between the effect of lactate-gel and metronidazole. Gynecol Obstet Invest. 1986;21(1):19–25. DOI: 10.1159/000298923

[48] Andersch B., Forssman L., Lincoln K., et al. Treatment of bacterial vaginosis with an acid cream: a comparison between the effect of lactate-gel and metronidazole // Gynecol. Obstet. Invest. 1986. Vol. 21. No. 1. P. 19–25. DOI: 10.1159/000298923

[49] Andersch B, Lindell D, Dahlén I, Brandberg A. Bacterial vaginosis and the effect of intermittent prophylactic treatment with an acid lactate gel. Gynecol Obstet Invest. 1990;30(2):114–119. DOI: 10.1159/000293230

[50] Andersch B., Lindell D., Dahlén I., Brandberg A. Bacterial vaginosis and the effect of intermittent prophylactic treatment with an acid lactate gel // Gynecol. Obstet. Invest. 1990. Vol. 30. No. 2. P. 114–119. DOI: 10.1159/000293230

[51] Armstrong-Buisseret L, Brittain C, et al. Lactic acid gel versus metronidazole for recurrent bacterial vaginosis in women aged 16 years and over: the VITA RCT. Health Technol Assess. 2022;26(2):1–170. DOI: 10.3310/ZZKH4176

[52] Armstrong-Buisseret L., Brittain C., Kai J., et al. Lactic acid gel versus metronidazole for recurrent bacterial vaginosis in women aged 16 years and over: the VITA RCT // Health Technol. Assess. 2022. Vol. 26. No. 2. P. 1–170. DOI: 10.3310/ZZKH4176

[53] Amatya R, Bhattarai S, Mandal PK, et al. Urinary tract infection in vaginitis: a condition often overlooked. Nepal Med Coll J. 2013;15(1):65–67.

[54] Amatya R., Bhattarai S., Mandal P.K., et al. Urinary tract infection in vaginitis: a condition often overlooked // Nepal Med. Coll. J. 2013. Vol. 15. No. 1 P. 65–67.

[55] Gottschick C, Deng ZL, Vital M, et al. The urinary microbiota of men and women and its changes in women during bacterial vaginosis and antibiotic treatment. Microbiome. 2017;5(1):99. DOI: 10.1186/s40168-017-0305-3

[56] Gottschick C., Deng Z.L., Vital M., et al. The urinary microbiota of men and women and its changes in women during bacterial vaginosis and antibiotic treatment // Microbiome. 2017. Vol. 5. No. 1. P. 99. DOI: 10.1186/s40168-017-0305-3

[57] Foxman B, Gillespie B, Koopman J, et al. Risk factors for second urinary tract infection among college women. Am J Epidemiol. 2000;151(12):1194–1205. DOI: 10.1093/oxfordjournals.aje.a010170

[58] Foxman B., Gillespie B., Koopman J., et al. Risk factors for second urinary tract infection among college women // Am. J. Epidemiol. 2000. Vol. 151. No. 12. P. 1194–1205. DOI: 10.1093/oxfordjournals.aje.a010170

[59] Ahmed H, Davies F, Francis N, et al. Long-term antibiotics for prevention of recurrent urinary tract infection in older adults: systematic review and meta-analysis of randomised trials. BMJ Open. 2017;7(5). DOI: 10.1136/bmjopen-2016-015233

[60] Ahmed H., Davies F., Francis N., et al. Long-term antibiotics for prevention of recurrent urinary tract infection in older adults: systematic review and meta-analysis of randomised trials // BMJ Open. 2017. Vol. 7. No. 5. DOI: 10.1136/bmjopen-2016-015233

[61] Foxman B, Barlow R, D’Arcy H, et al. Urinary tract infection: self-reported incidence and associated costs. Ann Epidemiol. 2000;10(8):509–515. DOI: 10.1016/s1047-2797(00)00072-7

[62] Foxman B., Barlow R., D’Arcy H., et al. Urinary tract infection: self-reported incidence and associated costs // Ann. Epidemiol. 2000. Vol. 10. No. 8. P. 509–515. DOI: 10.1016/s1047-2797(00)00072-7

[63] Ronald A. The etiology of urinary tract infection: traditional and emerging pathogens. Dis Mon. 2003;49(2):71–82. DOI:10.1067/mda.2003.8

[64] Ronald A. The etiology of urinary tract infection: traditional and emerging pathogens // Dis. Mon. 2003. Vol. 49. No. 2. P. 71–82. DOI: 10.1067/mda.2003.8

[65] Storme O., Tirán Saucedo J., Garcia-Mora A., et al. Risk factors and predisposing conditions for urinary tract infection. Ther Adv Urol. 2019;11:19–28. DOI:10.1177/1756287218814382

[66] Storme O., Tirán Saucedo J., Garcia-Mora A., et al. Risk factors and predisposing conditions for urinary tract infection // Ther. Adv. Urol. 2019. Vol. 11. P. 19–28. DOI: 10.1177/1756287218814382

[67] Brannon JR, Dunigan TL, Beebout CJ, et al. Invasion of vaginal epithelial cells by uropathogenic Escherichia coli. Nat Commun. 2020;11(1). DOI: 10.1038/s41467-020-16627-5

[68] Brannon J.R., Dunigan T.L., Beebout C.J., et al. Invasion of vaginal epithelial cells by uropathogenic Escherichia coli // Nat. Commun. 2020. Vol. 11. No. 1. P. 2803. DOI: 10.1038/s41467-020-16627-5

[69] O’Brien VP, Lewis AL, Gilbert NM. Bladder exposure to gardnerella activates host pathways necessary for Escherichia coli recurrent uti. Front Cell Infect Microbiol. 2021;11. DOI: 10.3389/fcimb.2021.788229

[70] O’Brien V.P., Lewis A.L., Gilbert N.M. Bladder exposure to gardnerella activates host pathways necessary for Escherichia coli recurrent uti // Front. Cell. Infect. Microbiol. 2021. Vol. 11. DOI: 10.3389/fcimb.2021.788229

[71] Rosen DA, Hooton TM, Stamm WE, et al. Detection of intracellular bacterial communities in human urinary tract infection. PLoS Med. 2007;4(12). DOI: 10.1371/journal.pmed.0040329

[72] Rosen D.A., Hooton T.M., Stamm W.E., et al. Detection of intracellular bacterial communities in human urinary tract infection // PLoS Med. 2007. Vol. 4. No. 12. DOI: 10.1371/journal.pmed.0040329

[73] Gilbert NM, O’Brien VP, Lewis AL. Transient microbiota exposures activate dormant Escherichia coli infection in the bladder and drive severe outcomes of recurrent disease. PLoS Pathog. 2017;13(3). DOI: 10.1371/journal.ppat.1006238

[74] Gilbert N.M., O’Brien V.P., Lewis A.L. Transient microbiota exposures activate dormant Escherichia coli infection in the bladder and drive severe outcomes of recurrent disease // PLoS Pathog. 2017. Vol. 13. No. 3. DOI: 10.1371/journal.ppat.1006238

[75] Diebold R, Schopf B, Stammer H, et al. Vaginal treatment with lactic acid gel delays relapses in recurrent urinary tract infections: results from an open, multicentre observational study. Arch Gynecol Obstet. 2021;304(2):409–417. DOI: 10.1007/s00404-021-06040-8

[76] Diebold R., Schopf B., Stammer H., et al. Vaginal treatment with lactic acid gel delays relapses in recurrent urinary tract infections: results from an open, multicentre observational study // Arch. Gynecol. Obstet. 2021. Vol. 304. No. 2. P. 409–417. DOI:10.1007/s00404-021-06040-8

[77] Swidsinski A, Loening-Baucke V, Mendling W, et al. Positive effects of local therapy with a vaginal lactic acid gel on dysuria and E. coli bacteriuria question our current views on recurrent cystitis. Arch Gynecol Obstet. 2012;285(6):1619–1625. DOI: 10.1007/s00404-011-2196-z

[78] Swidsinski A., Loening-Baucke V., Mendling W., et al. Positive effects of local therapy with a vaginal lactic acid gel on dysuria and E. coli bacteriuria question our current views on recurrent cystitis // Arch. Gynecol. Obstet. 2012. Vol. 285. No. 6. P. 1619–1625. DOI: 10.1007/s00404-011-2196-z

RIGHTS & PERMISSIONS

Eсо-Vector